Matt D. Galsky, MD, on Practical Clinical Implications of Using Atezolizumab, Platinum, and Gemcitabine to Treat Urothelial Carcinoma

Posted: Wednesday, March 8, 2023

Matt D. Galsky, MD, of the Icahn School of Medicine at Mount Sinai and Tisch Cancer Institute, discusses what the new findings on atezolizumab, platinum, and gemcitabine could mean for patients with previously untreated locally advanced or metastatic urothelial carcinoma. The results he reports are final overall survival rates from the phase III IMvigor130 study.

---